Elizabeth Hirshberg, PA
Surgical · Bellingham, WANPI 1992207278
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,456 of the $3,795 with a category attached, or 64.7%. 33 manufacturers reported payments, led by Boston Scientific at 26.7% of the total. Reporting peaked in 2022 at $1,278 and has fallen 88.7% since, to $144 in 2025. Among surgical clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $34.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Astellas Pharma US Inc$514
- Johnson & Johnson$239
- AbbVie$203
- Sumitomo Pharma America, Inc.$165
- Antares Pharma, Inc.$157
- plus $2K from 27 others
What the payments were for
- Travel & lodging$80921%
- Food & beverage$2,45665%
- Education$53014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,013 |
| Astellas Pharma US Inc | 8 | $514 |
| Johnson & Johnson | 8 | $239 |
| AbbVie | 7 | $203 |
| Sumitomo Pharma America, Inc. | 6 | $165 |
| Antares Pharma, Inc. | 7 | $157 |
| Urovant Sciences Inc | 3 | $149 |
| Myriad Genetic Laboratories, Inc. | 4 | $146 |
| Endo Pharmaceuticals Inc. | 7 | $112 |
| Medtronic | 4 | $105 |
| Rochester Medical Corporation | 4 | $100 |
| Sun Pharmaceutical Industries Inc. | 3 | $83 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $80 |
| Axonics, Inc. | 3 | $79 |
| 180 Medical, Inc. | 3 | $70 |
| Trevena, Inc. | 3 | $67 |
| Tolmar Pharmaceuticals, Inc. | 3 | $66 |
| Pfizer | 3 | $61 |
| Urogen Pharma, Inc. | 3 | $56 |
| Blue Earth Diagnostics | 2 | $48 |
| Progenics Pharmaceuticals, Inc. | 2 | $46 |
| Olympus America Inc. | 2 | $43 |
| Laborie Medical Technologies Corp. | 1 | $34 |
| Merck | 1 | $27 |
| Tolmar, Inc. | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Profound Medical Corp. | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Coloplast | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $15 |
| Bayer | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$749
How this compares
$3,795 in reported general payments places this provider in the 90th percentile of 404 surgical providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 96 | $75,189 |
| OrgovyxRelugolix | 20 | $55,796 |
| MyrbetriqMirabegron | 43 | $29,326 |
| EstringEstradiol | 19 | $10,155 |
| Estradiol | 84 | $6,572 |
| Methenamine Hippurate | 54 | $1,820 |
| NitrofurantoinNitrofurantoin Macrocrystal | 56 | $1,535 |
| Tamsulosin Hcl | 58 | $1,030 |
| DottiEstradiol | 15 | $939 |
| Trimethoprim | 30 | $918 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $673 |
| Finasteride | 21 | $350 |
| ProgesteroneProgesterone, Micronized | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $165 | $130,985116 claims |
| Astellas Pharma US IncMyrbetriq | $514 | $29,32643 claims |
| PfizerEstring | $61 | $10,15519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 surgical providers in Washington.
Other surgical in Bellingham
- Gretchen ThornerYakima$612K
- Jana FlenerRenton$93K
- Jeffrey StepanianKirkland$52K
- Jin Lo TomblinSpokane$21K
- Philip HujdicRenton$17K
- Mark MashitaEverett$16K
- Lee Or RutenbergSeattle$13K
- Wesley SumrallBremerton$8K
- Corbin BrokawSeattle$8K
- Matthew RothstromEdmonds$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.